Ask AI
ProCE Banner Activity

Emerging Targeted Therapies for HNSCC: A Focus on EGFR-Directed Bispecific Antibodies

Slideset

This text module reviews the evolving treatment landscape for recurrent or metastatic HNSCC, with a focus on emerging EGFR-directed bispecific antibodies. Learners will assess clinical evidence, safety considerations, and ongoing trials to explore how these novel targeted therapies may address current treatment gaps and shape future care.

Released: July 28, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who care for patients with HNSCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess approved therapies for the treatment of HNSCC to inform the selection of suitable patient candidates for therapeutic intervention   

  • Differentiate current unmet needs in the treatment of head and neck cancer and their impact on care delivery and overall patient outcomes

  • Appraise clinical data regarding the safety and efficacy of emerging targeted and immunotherapeutic agents and next generation radiotherapy modalities in the treatment of HNSCC

  • Distinguish the relevance of emerging targeted therapies, immunotherapeutic agents, and next generation radiotherapy within the HNSCC treatment paradigm and their positioning for real-world integration